Blog Notes

Key Considerations for Multi-Indication Products

Ted Haack

31st of August, 2023

The 2022 SVB Entries and Exits report showed that oncology and platform technologies continue to lead biotech investments and exits, and the majority of these are multi-indication products. With the biotech sector down ~50% vs. June 2021, and 159 public life science companies having negative enterprise values last week (per Tim Opler‘s excellent weekly industry update), I wanted to recap some insights from our recent Demy-Colton #virtualsalon on market access and pricing considerations for multi-indication products. We hope this article will provide some guidance on how to value these products, including dealing with the #IRA #pricing legislation, and help reduce some of the disconnects many CEO’s in the biotech industry are facing in their financing and partnership discussions.

Need a thought partner for your multi-indication project? We can help. See our capabilities and case study on thought leadership here.

Strategic Pricing for Optimal Valuation

Ted Haack

31st of August, 2023

I wanted to write a brief post (5 minute read, I promise) following up on our Demy-Colton #virtualsalon “Strategic Pricing for Optimal Valuation”. There were of course far more topics than we had time to discuss, so I put together 10 key points to summarize the panel discussion and address a few new items.  My gratitude to our fantastic panel of industry leaders Judy CampagnariJessica MartinezDennis Purcell and Denise Scots-Knight for a wonderful discussion.

Need a thought partner for your multi-indication project? We can help. See our capabilities and case study on thought leadership here.

A free tool to simplify decision-making in pharmaceutical tenders

Paola Colzani, Benjamin Tschumi and Sean Robbins

13th June 2023

Tenders are at the heart of procurement in European pharmaceutical markets. Public healthcare providers widely use tenders to enhance competition and reduce drug purchase prices, threatening pharmaceutical companies’ profitability.

 LatticePoint has developed a tool to simplify decision-making based on economic modeling.

All you need is to input the potential number of bidders interested in participating in the tender and the estimation of production costs. The output will provide a valuable price benchmark to increase profit and an estimation of the probability of winning the tender to evaluate participation.

 Do you want to be able to have quick predictions about tendering outcomes? Do you need help simplifying strategic decision-making?

Give our tendering tool a try and let us know what you think:

Gain early insights into the cost-effectiveness of early stage oncology products

Benjamin Tschumi

2nd May 2023

During the early stage of development of an oncology product, the estimation of its cost-effectiveness can be instrumental to understand how clinical characteristics and pricing influence its ICER .
Cost-effectiveness models are complex and lengthy to build; and aren’t always available early in the development process.
We developed Quick PartSA (Quick Partitioned Survival Analysis) to enable users to estimate the cost-effectiveness of an investigational intervention using a partitioned survival model. Instead of relying on patient-level survival data, this tool approximates survival curves using known OS and PFS survival probabilities and the hazard ratio for survival outcomes between an intervention and its comparator arm.
Quick PartSA can be useful to explore scenarios under which an intervention can reach cost-effectiveness.
Give QuickPartSA a try and let us know what you think:

Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets

OECD, Sean Robbins as external expert

8th September 2022

Price transparency for pharmaceuticals is a hot and delicate topic. To frame the necessary policy debate, the Organisation for Economic Co-operation and Development (OECD) undertook an exploration of the potential consequences of greater price transparency on market dynamics. The work included a roundtable and a series of semi-structured interviews, with participation by 19 experts in pharmaceutical pricing, economics of pharmaceutical markets, competition, and law. With an extensive review of the current practice and relevant literature as a preface, the resulting report presents the key findings from those consultations.

Our managing partner Sean Robbins was one of these 19 experts that provided input during this process. Have a look at the insightful outcome:

Need a thought partner for your complex strategic questions? We can help. See our capabilities and case study on thought leadership here

Multi-indication drugs: Can one price fit all?

Bárbara Magalhães

7th July 2022

An increasing number of medicines have shown to be effective in more than one indication, which leads to several price setting and reimbursement challenges as drug value might differ in each indication. Indication-based pricing (IBP) could solve some of the challenges of the current uniform price system, however, its implementation in Europe is still associated with major operational hurdles. What are the main factors influencing the market access of multi-indication drugs? How economically attractive is IBP for both payers and manufacturers? Which mechanisms are in place in Europe to minimize multi-indication pricing challenges and facilitate patient access? In this blog note, we are providing some insights on the subject.

Add-on payments mechanism: challenges and opportunities for access of innovative drugs in the hospital setting

Cristina Freire Sanz

3th May 2022

Inpatient healthcare services are contributing significantly to healthcare expenditures. In many countries, inpatient services (including medicines) are funded according to a DRG (Diagnosis-Related Group). Unfortunately, innovative, high-cost medicines at launch are often not sufficiently covered by these reimbursement systems which in turn disincentivizes hospitals to adopt and use these new treatment options. Why are DRG payment systems not made for high-cost medicines? What are the existing solutions for this issue? And what are the challenges and opportunities in the key markets? In this blog note, we are providing some insights on the subject.

Is Turkey pulling the plug on the medicines brought from abroad policy?

Efe Erdeş

5th April 2022

In December 2018, Turkey took its first measures to restrict the early access to medicines via the named patient program called “Medicines Brought from Abroad” list (MBFA, Yurtdışı İlaç Listesi) by limiting this benefit to a maximum of 3 years. The new law enforced manufacturers to apply for MA within these 3 years of duration of the program, and in case of failure of the MA filling, then the medicine might be constantly removed from the program. Accordingly, last December, the deadline for MA filling for the medicinal products supplied through this route prior to the amendment of 2018 was expired. What are the market access implications for those products that omitted the MA filling? Does MBFA still constitute an option for early access to Turkish market? What could be the best P&R route in Turkey to follow post-MBFA? In this blog note, we are providing some insights on the subject.

The new litmus test for early access in France: Is your product really innovative?

Karin Steinbach

7th March 2022

In July 2021, new French rules on early access to unauthorized medicinal products and off-label use of authorized medicinal products entered into force. Seven months into their implementation, the outcomes of the first evaluations are available. How is the new innovation-related criterion impacting the new assessments? Is HAS now stricter than ASNM has been? In this blog note, we are sharing some insights on the subject.

How safe is that orphan drug designation?

Sean Robbins

1st February 2022

An Orphan drug designation (ODD) can provide important incentives for a product during both clinical development and the market access stage. Although obtaining an ODD during a drug’s clinical development can be relatively easy, maintaining it at the time of regulatory approval has become increasingly difficult. In the following blog note, we discuss the requirements associated with maintaining an ODD in Europe, raise key questions for market access professionals about the relevance of having an ODD, and provide recommendations on how to optimize your chances of keeping the ODD.

New ways to pay for antibiotics

Natali Pennese

10th October 2021

Today, antimicrobial resistance is a serious and growing problem for healthcare systems, as it shrinks the range of treatment options available, setting many infections that were once easily treatable in a path to become deathly conditions. Paradoxically, the development and launch of new antibiotics have only been decreasing in the last years. Why has Pharma abandoned the antibiotics field, and what is being done by healthcare systems to make it again an attractive investment? In our blog note, we discussed those disincentives, as well as the most current policies being explored to tackle the issue in European countries.

Looking for more information? Get in touch with our team.